E
Egetis Therapeutics AB
Profile managed by Bizz IdEgetis / Emcitate
Suecia
11-50 employees
Description
Swedish biopharmaceutical company listed on Nasdaq Stockholm. Develops Emcitate® (tiratricol) for MCT8 deficiency (rare paediatric disease with no treatment). EU marketing authorisation in February 2025, launch in Germany in May 2025. Also develops Aladote® for paracetamol overdose.